Patent · US Active

Mutated factor X polypeptides and uses thereof for the treatment of haemophilia

US11085032B2 · kind B2 · utility

0Cited by

1References

1Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
UNIVERSITA DI PERUGIA · IT
American University of Beirut · LB
ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR

Inventors

Olivier Christophe · Le Kremlin-Bicêtre, FR
Cecile Denis · Le Kremlin-Bicêtre, FR
Peter LENTING · Le Kremlin-Bicêtre, FR

Key dates

Filing date	Apr 13, 2020
Grant date	Aug 10, 2021
Priority date	—
Expiry date	Apr 13, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.